PBAC's latest decision on Rasagiline: Recommended with restriction (2012). Considered for Parkinson disease as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect.
PBAC outcome
Recommended with restriction
Authority Required (STREAMLINED)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2011
Submissions
2
2011 → 2012
Eligible population
patients with Parkinson disease experiencing motor fluctuations who are currently receiving levodopa therapy
Therapy area
Neurology
Line of therapy
Later-line
Evidence base
RCT, cost-minimisation
Primary endpoint
QoL, change in mean total daily OFF time, Total UPDRS score in ON state